Semaglutide: a promising new glucagon-like peptide-1 receptor agonist

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 4, 2017, Pages 236-238

  Scheen, André J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE;

BODY WEIGHT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCAGON RELEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); SATIETY; STOMACH EMPTYING; TREATMENT DURATION; TREATMENT OUTCOME;

GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES;

EID: 85009781763     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30012-8     Document Type: Note

References (11)

1. 1 Meier, JJ, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
2. 2 Sorli, CH, Harashima, S-i, Tsoukas, GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre, phase 3a trial. Lancet Diabetes Endocrinol, 2017 published online Jan 16. http://dx.doi.org/10.1016/S2213-8587(17)30013-X.
3. 3 Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
4. 4 Moretto, TJ, Milton, DR, Ridge, TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30 (2008), 1448–1460.
5. 5 Garber, A, Henry, R, Ratner, R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
6. 6 Fonseca, VA, Alvarado-Ruiz, R, Raccah, D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 35 (2012), 1225–1231.
7. 7 Russell-Jones, D, Cuddihy, RM, Hanefeld, M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35 (2012), 252–258.
8. 8 Nauck, MA, Stewart, MW, Perkins, C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 59 (2016), 266–274.
9. 9 Umpierrez, G, Tofe Povedano, S, Perez Manghi, F, Shurzinske, L, Pechtner, V, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37 (2014), 2168–2176.
10. 10 Scheen, AJ, Which incretin-based therapy for type 2 diabetes?. Lancet 384 (2014), 1325–1327.
11. 11 Davies M, Pieber TR, Jabbour S, Hartoft-Nielsen M-L, Højbjerg Hansen OK, Rosenstock J. Dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes. Oral presentation at the 52nd annual meeting of the European Association for the Study of Diabetes, Munich, Germany; Sept 15, 2016, abstract 149.